Charles T Quinn
Charles T Quinn is an expert in Hematology at Cincinnati Children's Hospital Medical Center (United States). As of October 2026, ScienceLeadR ranks Charles T Quinn in the top 1% of experts worldwide for Anemia. Charles T Quinn has authored 270 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 1 of them ongoing. SLR score: 1,086 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Pediatrics - Genetics - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1996 - 2026
Number : 270
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Predict less, prevent more: A familiar mantra for sickle cell anaemia? PMID 42509208 — cells, stroke, anemia | Br J Haematol | 2026 | 0 |
| Seroprotection after Measles Vaccination in Children with Sickle Cell Anemia Receiving Hydroxyurea. PMID 42448315 — cells, antibody formation, vaccines, anemia, sickle cell, anemia, measles, vaccination, therapeutics, hematologic diseases, child, hydroxyurea | Blood Adv | 2026 | 0 |
| NICU to neighborhood: structural drivers shape health inequities for preterm infants. PMID 42288641 — infant, premature, pediatrics, infant | Pediatr Res | 2026 | 0 |
| Renin-Angiotensin-Aldosterone System Inhibition Exacerbates Anemia in Sickle Cell Disease. PMID 42224366 — cells, hemoglobins, aldosterone, anemia, sickle cell, anemia, losartan, renin, angiotensins, erythropoietin, therapeutics | Blood | 2026 | 0 |
| More disease-modifying therapies for sickle cell disease: Are small molecules and drug repurposing the way forward? PMID 42115086 — cells, hemoglobins, hematology, anemia, sickle cell, pharmaceutical preparations, therapeutics, small molecules | Semin Hematol | 2026 | 0 |
Clinical Studies 19
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 6
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Effectiveness of Nontraditional Hydroxyurea Algorithms Novel and Clinical Evaluations (ENHANCE) NCT07177300 — cells, blood, anemia, sickle cell, anemia, aging, algorithms, thalassemia, pharmacogenomic variants, maximum tolerated dose, research, hematologic tests, hydroxyurea | Phase 4 | Recruiting | 2024 |
LeadR Networks
Main global connection map